Preamble
The American College of Cardiology (ACC) and the American Heart Association (AHA) recognize the importance of refining the lexicon used to describe the process and outcomes of clinical care, whether in randomized trials, observational studies, registries, or quality improvement initiatives. Broad professional agreement on a common vocabulary with common definitions will facilitate cross-study comparisons or, when advantageous, combining of data across studies and improving the assessment of any project's generalizability to clinical practice. To further efforts aimed at standardizing such a lexicon, the ACC and AHA have undertaken to develop and publish clinical data standards-sets of standardized data elements and corresponding definitions that can be used in a variety of data collection efforts for a range of cardiovascular conditions. It is hoped that these clinical data standards will:
1. Improve cross-comparison of results and clinical outcomes between different trials and registries. 2. Facilitate the development and conduct of future registries, at both hospital and national levels, by providing a list of major variables, outcomes, and definitions. 3. Facilitate measurement for quality improvement programs. 4. Become the basis for a standardized medical documentation process with the anticipation that the medical record will progress to an electronic format.
The ACC/AHA Task Force on Clinical Data Standards makes every effort to avoid any actual or potential conflicts of interest that might arise as a result of an outside relationship or a personal interest of a member of the writing panel.
Specifically, all members of the writing panel are asked to provide disclosure statements of all such relationships that might be perceived as real or potential conflicts of interest. These statements are reviewed by the parent task force, reported orally to all members of the writing panel at the first meeting, and updated as changes occur. The ACC/AHA Task Force on Clinical Data Standards selects cardiovascular conditions and procedures that would benefit from the creation of a standard dataset. Experts in the subject are selected to examine/consider existing data standards and develop a comprehensive, yet not exhaustive, standard dataset. Users should understand that, when undertaking a data collection effort, only a subset may be needed or, conversely, they may want to consider whether it may be necessary to collect some elements not listed. For example, in the setting of a randomized clinical trial of a new drug, additional information would likely be required regarding study procedures and drug therapies.
The ACC and AHA aim to standardize the language used to describe cardiovascular diseases and procedures, enhance consistency in cardiology, and increase opportunities for sharing data across various data sources. The ultimate goal of ACC/AHA clinical data standards is to contribute to the infrastructure necessary for accomplishing the ACC/AHA's mission of fostering optimal cardiovascular care and disease prevention.
The ACC and AHA support the goals of their members to improve cardiovascular care and disease prevention through professional education, promotion of research, development of guidelines and standards for cardiovascular care, and fostering a policy that supports optimal patient outcomes. Both the ACC and the AHA recognize the importance of the use of clinical data for patient management, in the assessment of patient outcomes, and in research efforts focused on improving the clinical treatment of patients.
As a component of this objective, the ACC/AHA clinical data standards concentrate on the identification, definition, and standardization of data corresponding with various clinical topics in cardiology. The primary goal of clinical data standards is to assist in the collection of data by providing an initial platform of data elements and corresponding definitions applicable to various disease conditions in cardiology.
These key elements and definitions are a compilation of variables applicable in the measurement of patient clinical management and outcomes, and for research and epidemiological assessments.
The Health Insurance Portability and Accountability Act (HIPAA) privacy regulations, which went into effect in April 2003, have heightened all practitioners' awareness of our professional commitment to safeguard our patients' privacy. Our goal is to treat every patient's health information with the same respect and courtesy as their person. The HIPAA privacy regulations (http:// www.hhs.gov/ocr/combinedregtext.pdf, page 31) specify which elements are considered "protected health information." These elements may not be disclosed to third parties (including registries and research studies) without the patient's written permission. Protected health information may be included in databases used for health care operations under a data use agreement. Research studies using protected health information must be reviewed by an Institutional Review Board or a Privacy Board.
We have included identifying information in all clinical data standards, to facilitate uniform collection of these elements when appropriate. For example, a longitudinal clinic database may contain these elements, because access is restricted to the patient's caregivers. Conversely, registries may not contain protected health information, unless specific permission is granted by each patient. These fields are indicated as protected health information (PHI) in the data standards.
Our understanding of the importance of data element standardization, the backbone of clinical care, clinical research, and quality performance measurement, derives from experience with clinical care, clinical research, and quality performance measurement. In clinical care, caregivers communicate with each other through a common vocabulary. The integrity of clinical research depends in large part on firm adherence to prespecified procedures for patient enrollment and follow-up; these procedures are guaranteed through careful attention to definitions enumerated in the study design and case report forms. When data elements and definitions are standardized across studies, comparisons, pooled analyses, and metaanalyses are enabled, thus deepening our understanding of individual clinical trials.
The recent development of quality performance measurement initiatives, particularly those for which comparison of providers is an implicit or explicit aim, has further raised awareness among the professional community about the importance of data standards. For the first time, a wide audience, including non-medical professionals such as payers, regulators, and consumers, may draw conclusions about care and outcomes. For understanding and comparison of care patterns and outcomes to be fair, the data elements that comprise the descriptions of these patterns and outcomes of care must be clearly defined, consistently used, and properly interpreted by a broader audience than ever before.
Paul A. Heidenreich, MD, MS, FACC Chair, ACC/AHA Task Force on Clinical Data Standards
I. INTRODUCTION
The syndrome of heart failure (HF) is a common manifestation of the later stages of various cardiovascular diseases, including coronary artery disease, hypertension, valvular disease, and primary myocardial disease. It is the most common reason for hospitalization among older individuals (1) , and its appearance usually foreshadows the need for ongoing care for the duration of the patient's life. Therapy for HF has benefited from scientific investigations into basic molecular mechanisms of disease (2, 3) from advances in engineering, instrumentation, and surgery (4) and from large multicenter trials (5) (6) (7) and registries (8, 9) . Increasingly, care of patients with HF, particularly advanced HF, may take place in specialized clinics using a team approach (10 -12) . In addition, growing national interest in quality of treatment has focused scrutiny on patterns and outcomes of HF care (13, 14) .
Heart failure was identified for development of data standards by the ACC and the AHA. As with the first condition, acute coronary syndromes (ACS) (15) , and the second condition, atrial fibrillation (AF) (16) , the goal of the data standards is to provide a standardized information platform that will be useful in a variety of situations, particularly clinical trials, clinical registries, and quality performance measurement. Similar to the writing committees for ACS and AF clinical data standards, the ACC/AHA Writing Committee to Develop Clinical Data Standards for Heart Failure proceeded to develop data element definitions with the understanding that they might be useful in a variety of circumstances:
• Clinical programs, such as HF clinics, where many providers work together to achieve specific and specified goals for the care of patients with HF. • Clinical registries, for ongoing care, prospective epidemiologic research, or prospective quality performance measurement. • Clinical research, particularly prospective randomized clinical trials where eventual pooled analysis or metaanalysis is anticipated. • Quality performance measurement initiatives, providerbased or external, retrospective or prospective. • Organization and design of electronic medical information initiatives, such as electronic medical records, pharmacy databases, or computerized decision support.
II. METHODOLOGY

A. Writing Committee Composition
The ACC/AHA Task Force on Clinical Data Standards selected members for the ACC/AHA Writing Committee to Develop Clinical Data Standards for Heart Failure (Writing Committee). The Writing Committee consisted of 10 members who are active in clinical research in HF, clinical programs (HF clinics, transplant programs, centers of excellence), HF registries, and quality performance measurement initiatives. The Writing Committee included membership from the U.S., Great Britain, and Canada so as to ensure balance in the selection of data elements and consideration of variations in practice worldwide. A representative from cardiovascular nursing provided expertise in the area of patient education. To ensure consistency between the clinical data standards and other ACC/AHA HF documents, the Task Force also appointed representatives from the ACC/AHA Heart Failure Guideline Update Writing Committee and the ACC/AHA Heart Failure Performance Measures Writing Committee.
B. Relationships With Industry
The American College of Cardiology makes every effort to avoid any actual or potential conflicts of interest that may arise as a result of an outside relationship or a personal, professional, or business interest of a member of the writing panel. Specifically, all members of the writing group are required to complete and submit a disclosure form showing all such relationships that might be perceived as real or potential conflicts of interest. These statements are reviewed by the ACC/AHA Task Force on Clinical Data Standards, reported orally to all members of the writing panel at the first meeting, and updated as changes occur. Please see Appendix B for Writing Committee relationships with industry and Appendix C for relationships with industry information for peer reviewers of this document.
C. Review of the Literature and Existing Data Definitions
The (19) were developed simultaneously with the HF data standards, with frequent exchange of information between these two committees. Other research articles, clinical trials, and reference sources were consulted as needed and are cited throughout this document.
D. Prioritizing Data Elements
After the Writing Committee reviewed the HF guidelines, other pertinent literature, and the data definitions from related sources, a comprehensive list of possible data elements to include in this set was created. This initial list aimed at capturing the universe of potential elements with the understanding that, by necessity, this set of data elements must be limited to those elements most likely to be needed in data collection efforts for research, clinical care, and quality improvement. From this initial list, the Writing Committee graded the importance of including each data element as "high," "medium," or "low." All of the data elements with an average "high" score and the majority of those with an average "medium" score were maintained in the set. The rest of the elements were not defined at this time, but they are maintained as possible elements to be defined and added at a later time.
The process of writing and revising data element definitions caused many data elements to move in or out of the set for a variety of reasons. In some instances, an element that on its own may have been ranked "low" was necessary to complete a subset of elements pertaining to a related concept. Conversely, an element that was ranked as "high" may later have been determined to be impossible to define in a manner that facilitates consistent data collection, or its content may have been determined to be contained within another data element. In this fashion, the process of prioritizing, adding, and removing data elements continued throughout the Writing Committee's process.
E. Defining Data Elements
Members of the Writing Committee drafted definitions for those data elements deemed to have priority for the first publication of the HF data standards. Each writer received a template to assist in drafting the definitions and to provide for a structured format across authors. Members were encouraged to write definitions broad enough to be applicable in a variety of data collection settings, but specific enough that the data elements can be uniformly interpreted. Data elements have also been defined to be usable in both inpatient and outpatient settings.
Writing team members received sample definitions from a variety of existing sources (see Section "C. Review of the Literature and Existing Data Definitions"). Data definitions were linked whenever possible to the evidence-based national guidelines, specifically the ACC/ AHA 2005 HF Guideline Update (18) . To ensure consistency across ACC/AHA clinical data standards, writers were instructed to use an existing ACC/AHA definition verbatim unless there was a reason related to HF to change that definition.
Similar to guidelines and performance measures, data standards require regular review and updating. At the anniversary of the data standards publication, the Writing Committee chair, in conjunction with Writing Committee members, will review the data standards to ascertain whether or not modifications should be considered. Published ACC/AHA practice guidelines are reviewed one year after publication to determine whether significant advances have occurred in clinical practice to warrant changes in recommendations. To keep current, whenever the relevant guideline is updated the associated data standards will be reviewed and revised to reflect those changes.
F. Consensus Development
The ACC/AHA data standards are consensus, teamwritten documents that are based on judgments of experts in the field of cardiology. This Writing Committee met several times, both in person and through conference calls, over the course of several months to define and refine the data elements. Throughout the creation of the data element set, consensus was developed through discussions (either during face-to-face meetings or conference calls), e-mails, and sometimes written votes. The process of consensus development allowed for the incorporation of minority opinions in the few instances when a group consensus could not be achieved.
G. Peer Review, Public Comment, and Board Approval
The set of HF data elements was independently reviewed by three official reviewers nominated by the ACC and two official reviewers nominated by the AHA, the ACC/ AHA Heart Failure Guideline Update Writing Committee chair, the ACC/AHA Task Force on Clinical Data Standards, and four independent content reviewers. To further increase its applicability, the document was posted on the ACC Web site (www.acc.org) for a 30-day public comment period. The document was approved for publication by the governing bodies of the American College of Cardiology and the American Heart Association. The document has been formally endorsed by the Heart Failure Society of America (HFSA). To determine whether a revision is necessary, these clinical data standards will be reviewed a year after publication and yearly thereafter by the ACC/AHA Task Force on Clinical Data Standards.
H. Considerations for Use of Data Elements and Definitions
Although the ACC/AHA is not launching this set of data element definitions as the precursor to a national registry, it recognizes that definitions cannot be written effectively without the context of their intended use. The Writing Committee determined three major environments of data collection efforts:
The needs of clinical researchers are frequently unique to the specific research objective. This necessitates specific data element design and definitions, and the definitions proposed in this document may be considered as a starting point. In contrast, quality performance measurement, particularly when quality comparison is the goal, requires standard definitions for all data elements. When caregivers anticipate outcomes research based on their patients' care and experiences, uniform definitions are also strongly advised. Discussion of the considerations for use in clinical care and quality performance measurement was as much a component of the consensus development process as were the data definitions themselves.
It should be noted that clinical data standards present a model of elements that might be employed in data collection efforts, such as operating a registry, and are not functional databases in themselves.
I. Special Considerations and Challenges for HF Data Standards
Several special considerations were raised by the Writing Committee in its deliberations about which data elements to include and how to define them. 1. Uses for HF data standards. In considering heart failure data elements, their importance and their use for specific goals need to be borne in mind. For clinical care, elements pertaining to patient assessment and medical decision-making are paramount. For clinical research, elements pertaining to patient classification and outcomes are most important. For quality performance measurement, elements pertaining to care patterns and patient characteristics modulating care patterns take precedence. For example, for a clinician following a patient with HF, specific physical examination findings that dictate alterations in management are more important to determine than even the eventual outcome, whereas for clinical research the importance of these data elements is reversed. For quality performance measurement, elements describing the health care provider's decisionmaking (what the provider did and why) are important to elucidate.
Balance between focus and comprehensiveness.
Although it may be tempting to develop a very comprehensive data element catalogue encompassing every imaginable data need or use, the Writing Committee focused on commonly collected data elements to best focus and enable the use of these data elements in many situations by many users. In particular, the Writing Committee focused on the care of adults with HF. We acknowledge that congenital heart disease may be accompanied by HF, but have proceeded with the understanding that data elements specific to these conditions can be added at a later time or can be incorporated into a similar data standards effort directed toward congenital heart disease. 3. Balance between "primary" and "summary" data elements. In the process of diagnosis and treatment, clinicians gather detailed clinical information, synthesizing the details into a formulation and plan for each patient. It follows, then, that data elements making up a clinical dataset may consist of many individual data elements (e.g., the details of coronary anatomy assessed by angiography) or of summary concepts (e.g., the number of diseased coronary vessels or the physician's assessment that coronary artery disease is or is not a contributing factor to the patient's HF syndrome). More often than not, the committee emphasized primary data elements for those features characterizing the HF syndrome and summary data elements for etiologic and therapeutic characteristics. It was recognized, however, that specific projects involving, for example, a diagnostic test or a therapeutic technique, would amplify these core, summary measures with a richer vocabulary of primary data elements. 4. Variety of disease states leading to HF. Heart failure is a syndrome, not a disease. It is a physiologic state resulting from a variety of disease conditions and clinical situations including coronary artery disease, hypertension, valvular disease, hypertension, infection, cancer chemotherapy, and more. Given the Writing Committee's focus on data elements pertaining to the HF syndrome and its care, the data elements contained herein will be most useful for data collection efforts directed toward patients in Stage C or Stage D heart failure as defined by the ACC/AHA 2005 HF Guideline Update staging classification scheme (18) . 5. Acute and chronic care, inpatient and outpatient care venues. In contrast to acute coronary syndromes, HF is a chronic condition, usually with acute manifestations and exacerbations. Clinical care and clinical research are, in general, oriented toward gathering information prospectively about chronic outpatient-based care, whereas most quality performance measurement efforts are directed toward acute care received during hospitalization, usually gathered retrospectively. The Writing Committee con-sidered data elements pertinent to the full range of acute and chronic care provided to these patients. The data elements are intended to be useful for both inpatient and outpatient care venues. 6. Therapy for HF. Defining data elements to describe therapy for HF is a particular challenge. The Writing Committee recognizes that for clinical care, detailed information about therapy is essential. Other uses for these data elements require a summary approach. Given the variety of potential uses of these data standards, the Writing Committee recommends collecting information about medications as total daily dose prescribed at outpatient encounters or upon discharge from acute care hospitalization, and as summary information for therapeutic procedures such as coronary revascularization device implantation. Specific registries and clinical trials of treatment would be expected to specify additional data elements to supplement the summary elements outlined in this document. 7. Outcomes assessment for HF. Mortality and hospitalization outcomes are more comparable and understandable when adjusted for risk; current understanding of important risk-adjustment domains for these outcomes has informed the inclusion of specific data elements. In addition, because HF is a chronic condition, HF care also encompasses outcomes such as symptom burden, functional status, psychological state, compliance with a therapeutic regimen, self-management, and quality of life (11,20 -23) . (Please see Appendix A for a more detailed discussion of assessment and interpretation.)
III. HF CLINICAL DATA STANDARD ELEMENTS AND DEFINITIONS
A. Patient Demographics (Table 1)
Patient demographic information is used for patient identification for longitudinal care, for demographic grouping to assess issues of access and care quality for traditionally disadvantaged groups, and for risk adjustment. Association of any health information with unique patient identifiers and/or demographic information that can be linked to the individual patient (indicated by an asterisk in Table 1 ) identifies the dataset as "protected health information." Unique patient identification information (Social Security number or medical record number) is necessary and appropriate for longitudinal clinical care, but given current legislation protecting patients' privacy (24) , such information is not included in multiinstitution registries unless appropriate informed consent is obtained from all patients. For other uses, patient privacy concerns may need to be considered by hospital privacy officers and/or institutional review boards (IRBs). Insurance payor Indicate the patient's primary insurance payor for this admission. Choose one of the following: • Government: Refers to patients who are covered by government-reimbursed care. In the U.S., this includes: -Medicare -Medicaid (including all state or federal Medicaid-type programs) -Champus -Veterans Health Administration -Department of Defense -Other federal group (specify) • Commercial: refers to all indemnity (fee-for-service) carriers and preferred provider organizations (PPOs). • HMO: refers to a health maintenance organization characterized by coverage that provides health care services for members on a pre-paid basis. • None: refers to individuals with no or limited health insurance; thus, the individual is the payor regardless of ability to pay. Only mark "None" when "self" or "none" is denoted as the first insurance in the medical record.
Government payor type
If the patient's primary insurance payor for this encounter is "Government," choose the type of government insurance: 
B. Medical History (Table 2)
Information about patients' medical history is important in quality performance measurement, clinical research, and clinical care. Presence of cardiac risk factors have both prognostic and management implications, as do elements describing current cardiovascular conditions. History of non-cardiac conditions may denote absolute or relative contraindications to various therapies, or may significantly impact outcomes. Inclusion of data elements pertinent to medical history is, therefore, important to clinical decision-making, to design of quality performance measures, and to risk-adjusted outcomes assessment. For most purposes, these data elements can be recorded as either present or absent. Year of onset may be helpful, especially when data collection is used for longitudinal clinical follow-up. More detailed information about the severity of each condition (e.g., record of prior hospitalizations or specifics of therapy for the condition) might be considered for certain users. Table 2 . Medical History
Data Element Definition
Medical History: Heart Failure Risk Factors
History of smoking History confirming cigarette smoking in the past. Choose from the following categories:
• Current: smoking cigarettes within one month of this encounter • Recent: stopped smoking cigarettes between 1 month and 1 year before this encounter • Former: stopped smoking cigarettes more than one year prior to this encounter • Never: never smoked cigarettes For current or former smokers, total pack years may be useful. Family history (parent or sibling) of sudden cardiac death, defined as natural death due to cardiac causes, heralded by abrupt loss of consciousness. The time and mode of death are unexpected even though preexisting heart disease may have been known to be present (26) . Sudden death without obvious cause is considered sudden cardiac death. Traumatic death subsequently proven to be due to sudden loss of control due to a cardiac problem is included. Age at time of sudden cardiac death may be specified. 
History of myocardial infarction
History of myocardial infarction as determined by any of the following: • Hospital admission for acute myocardial infarction • EKG report indicating previous (old) or acute myocardial infarction • Increase in biochemical marker (creatine kinase or troponin) consistent with myocardial infarction. Note that low elevation in troponin level may be seen in patients with heart failure and should not by themselves be considered diagnostic of infarction (15) • Patient reports history of acute myocardial infarction or heart attack. Total number of myocardial infarctions and year of the first and the most recent episode may be helpful.
Previous coronary artery bypass graft (CABG)
Coronary artery bypass graft surgery prior to the current encounter. Total number of CABG procedures and year of most recent may be helpful.
Previous percutaneous coronary intervention (PCI)
PCI of any type (balloon angioplasty, atherectomy, stent, or other) prior to the current encounter. Total number of PCI procedures and year of most recent may be helpful.
Previous pacemaker or ICD implantation
Pacemaker or ICD implantation prior to the current encounter. Device type (pacemaker, ICD, combination), cardiac chamber(s) involved, and year of implantation may be helpful.
History of peripheral embolic event
History of peripheral embolic event as determined by:
• Hospital admission for peripheral embolic event • Patient reports history of peripheral embolic event • Report of diagnostic or therapeutic procedure indicating presence of peripheral embolic event (for example, embolectomy, angiography; nuclear study; ultrasound study) Year of the first episode and number of events may be helpful. 
History of cerebrovascular disease
History of cerebrovascular disease, documented by any one of the following:
• Cerebrovascular ischemic or hemorrhagic stroke: patient has a history of stroke (i.e., any focal neurological deficit of abrupt onset caused by a disturbance in blood supply that did not resolve within 24 hours) confirmed by a standard neurological examination with or without a positive imaging study, or an event of presumed ischemic origin that did not resolve within 24 hours, but the imaging showed a new lesion. • Transient ischemic attack (TIA): patient has a history of any sudden new focal neurological deficit of presumed ischemic origin as determined by a standard neurological exam that resolved completely within 24 hours, with a brain image study not revealing a new lesion. • Noninvasive/invasive carotid test with greater than or equal to 75% occlusion • Previous carotid artery surgery • Previous carotid angioplasty Year of the first and most recent episode may be helpful.
Level of disability following stroke
Level of disability following stroke:
• Recovered • Minor persisting disability • Major persisting disability History of peripheral arterial disease History of peripheral arterial disease may include:
• Claudication either with exertion or at rest • Amputation for arterial vascular insufficiency • Vascular reconstruction, bypass surgery, or percutaneous intervention to the extremities • Documented aortic aneurysm Year of the first episode and number of events may be helpful.
History of rheumatic valvular disease
History of primary valvular disease may include:
• History of acute rheumatic fever/carditis (usually determined through correspondence with major and minor criteria [28] ) • History of valve disease with echocardiographic findings suggestive of or diagnostic of rheumatic valvular disease Year of the first episode may be helpful.
History of other valvular disease etiology
History of valvular disease of other etiology (specify):
• Congenital (present at birth or occurring association with congenital heart disease syndrome) • Degenerative (acquired during adulthood, usually after age 50) • Infectious (acquired as a result of infectious endocarditis) • Toxic (for example, as a result of exposure to fenfluramine phentermine dexfenfluramine) • Other (specify) Year of the first episode may be helpful. 
History of acute renal insufficiency
History of reduced renal function (see "History of chronic renal insufficiency" element) for less than 3 months.
Year of occurrence of and precipitant for acute renal insufficiency may be specified.
History of dialysis
History of renal dialysis, either by:
• Hemodialysis • Peritoneal dialysis Year of onset may be helpful.
History of chronic lung disease
History of chronic lung disease (e.g., chronic obstructive pulmonary disease, chronic bronchitis, emphysema) or currently being chronically treated with inhaled or oral pharmacological therapy (e.g., beta-adrenergic agonist, anti-inflammatory agent, leukotriene receptor antagonist, or steroid).
Year of onset (first diagnosis) may be helpful.
History of dementia History of dementia, Alzheimer's disease, chronic confusion (at least one month in duration), or senility.
History of depression
History of treated depression, or currently taking antidepressant medication. Note if past or present episode has or is currently requiring drug treatment or electroconvulsive therapy (ECT).
History of liver disease History of chronic hepatitis or cirrhosis.
History of lupus or collagen vascular disease
History of collagen vascular disease such as lupus erythematosis, scleroderma, rheumatoid arthritis.
History of musculo-skeletal disease
History of primary musculo-skeletal disease, including muscular dystrophy, myasthenia gravis, dermatomyositis.
History of malignancy History of cancer, excluding non-melanoma skin cancers. Cancer site and date of first diagnosis may be helpful.
History of influenza immunization
History of influenza immunization.
Month and year of most recent immunization should be noted.
History of pneumococcal immunization
History of pneumococcal immunization.
History of urinary continence
History of urinary continence. Choose from the following categories:
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C. Patient Assessment: Current Symptoms and Signs (Table 3)
For patients with HF, assessment of signs and symptoms is directed toward evaluation of volume status and cardiac output. For all symptoms reported by the patient, consider collecting time-frame (onset, current, course, and so on) and change in symptoms since last visit (better, worse, unchanged). For inpatient care encounters, the first patient assessment (history and physical examination) should be reported.
Often these data can be captured with health status instruments. Please see Appendix A for discussion of systematic collection of patient's functional status using structured survey/questionnaire instruments. 
Orthopnea
Patient describes at least one of the following:
• Uncomfortable awareness of breathing while in a supine position • Positioning with 3 or more pillows or in a chair or recliner to maintain comfortable breathing during sleep • Recurrent supine cough without other known cause may be an orthopnea equivalent Date of onset and duration may be helpful.
Paroxysmal nocturnal dyspnea
Patient describes awakening suddenly from sleep with uncomfortable awareness of breathing, or with general distress relieved by the upright position. Any report of this symptom lasting greater than 5 minutes is considered positive. Date of onset and duration may be helpful.
Weight gain or loss
Amount of weight gain or loss, in pounds or kilograms, as reported by the patient. Time frame over which weight change occurred should be noted.
Swelling
Patient reports swelling or puffiness in extremities, abdomen, and/or other areas. Date of onset and duration may be helpful.
Fatigue
Patient describes unusual tiredness and inability to perform usual activities.
Date of onset and duration may be helpful.
Angina
Angina refers to previous or current symptoms described as chest pain or pressure, jaw pain, arm pain, or other equivalent discomfort suggestive of cardiac ischemia. The Canadian Cardiovascular Society angina classification (29) is useful in determining the level of angina: • Grade I: ordinary physical activity does not cause angina-for example walking or climbing stairs, angina occurs with strenuous or rapid or prolonged exertion at work or recreation. • Grade II: slight limitation of ordinary activity-for example, angina occurs walking or stair climbing after meals, in cold, in wind, under emotional stress or only during the few hours after awakening, walking more than two blocks on the level or climbing more than one flight of ordinary stairs at a normal pace and in normal conditions. • Grade III: marked limitation of ordinary activity-for example, angina occurs walking one or two blocks on the level or climbing one flight of stairs in normal conditions and at a normal pace. • Grade IV: inability to carry on any physical activity without discomfort-angina syndrome may be present at rest. Year of onset (first diagnosis) may be helpful.
Syncope
Sudden loss of consciousness not related to anesthesia, with spontaneous recovery as reported by patient or observer. Patients losing consciousness prior to an implantable cardiac defibrillator (ICD) discharge will be considered to have syncope.
Date of most recent episode may be helpful.
D. Patient Assessment: Summary Assessment (Table 4)
Specific HF etiologies are provided for those data collection efforts that require a more specific delineation than "ischemic or non-ischemic." The possible etiologies allow for a pick-andchoose approach. A primary etiology and/or multiple etiologies may be chosen. The definitions of HF etiologies have been constructed to imply causality and not merely association. The list of potential etiologies represents a compromise between brevity and comprehensiveness.
Although the New York Heart Association (NYHA) functional class (30) has proven useful as a measure summarizing the patient's overall HF symptom burden, it may be imprecise, subject to substantial interobserver variability, and may change over time. Heart failure stage (18) and patient-reported health status (21, 31, 32) are emerging as important constructs for delivering and evaluating HF care. Table 3 Continued
Data Element Definition
Physical Examination
Heart rate Heart rate (beats per minute) recorded closest to the time of presentation to the health care facility and/or on discharge (for inpatient). Specify whether heart rate is regular or irregular. Heart rate may be ascertained from electrocardiographic tracing or from record of physical examination.
Systolic and diastolic blood pressure
Systolic and diastolic blood pressure (mm Hg) recorded closest to the time of presentation to the health care facility. Patient position (supine, sitting, other) may be noted.
Jugular venous pressure
The estimated height of the mean jugular venous waveform above the right atrium in cm. When expressed as cm without further description, the number should be recorded as written. When it is expressed as cm above the sternal angle, 5 cm should be added to the number recorded. In the absence of a numerical estimate of jugular venous pressure, "jugular venous distension (JVD)," "distended neck veins," and "halfway to the jaw" or "to the angle of the jaw" would be recorded as positive for elevated jugular venous pressure. Any of the following conditions indicates ischemic heart disease:
• At least one major epicardial coronary artery with more than 70% obstruction by coronary angiography • History of acute myocardial infarction associated with wall motion abnormality by echocardiography or gated blood pool imaging • Stress testing (with or without imaging) diagnostic of coronary artery disease Evidence for valvular heart disease Primary valvular disease:
• Moderately severe or severe, or 3ϩ or 4ϩ aortic insufficiency • Moderately severe or severe, or 3ϩ or 4ϩ mitral insufficiency with echocardiographic evidence that mitral insufficiency is a primary abnormality, and not secondary to ventricular dilation • Moderately severe or severe aortic stenosis defined by estimated aortic valve area by catheterization or Doppler echocardiography of less than or equal to 1.0 cm 2 • Moderately severe or severe mitral stenosis defined by estimated mitral valve area by catheterization or echocardiography of less than 1.0 cm 2 Contributory valvular disease:
• Valve disease that is felt to be significant but does not fulfill the above definitions Evidence for myocardial infiltrative or storage disease • Systemic amyloidosis by biopsy • Hemochromatosis by biopsy or by serum markers in the presence of clinical evidence of multi-organ involvement • Heart failure in a patient with a storage disease known to involve the myocardium, including Fabry disease, Gaucher disease, or the glycogen storage diseases
Evidence for inflammatory myocarditis
• Biopsy-proven myocarditis • Sarcoidosis with biopsy evidence or diagnostic pulmonary radiographic appearance with reduced left ventricular systolic function • Documented Chagas disease Evidence for primary myocardial hypertrophic muscle disease Any of the following conditions indicates evidence for primary myocardial hypertrophic muscle disease:
• Evidence for symmetric or asymmetric hypertrophy with or without outflow tract obstruction • Congenital muscular dystrophy Evidence for hypertensive cardiomyopathy One of the following conditions must be met:
• Untreated systolic blood pressure greater than 160 mm Hg or diastolic greater than 105 mm Hg for at least 3 months • Hypertension requiring at least 2 drugs for control for at least 5 years • Presence of diabetes and hypertension, treated or untreated • Documented left ventricular hypertrophy (preferably by echocardiography or MRI) • Absence of other etiologies for heart failure Evidence for toxic cardiomyopathy • Alcohol abuse present for at least 5 years as defined by either heavy alcohol consumption (i.e., 75 g/day at least 5 days/wk) or alcohol dependence • Cocaine use • Ephedrine use • Temporally-related exposure to a drug or substance known to cause cardiomyopathy, including chemotherapeutic agents(s) and radiation to the chest Evidence for pregnancyrelated cardiomyopathy
Onset of cardiomyopathy associated with pregnancy (peri-, post-partum).
Indicate whether cardiomyopathy appears to be: • Reversed/resolved, or • Irreversible, causing permanent damage to the myocardium Evidence for thyroid disorderrelated cardiomyopathy Presence of otherwise unexplained cardiomyopathy associated with thyroid disorder.
Evidence for arrhythmogenic right ventricular dysplasia (ARVD) cardiomyopathy
Arrhythmogenic right ventricular dysplasia (AVRD) is characterized by progressive fibrofatty replacement of right ventricular myocardium and right ventricular dysfunction, regional or global, usually demonstrated by echocardiography or cardiac magnetic resonance imaging. It is associated with arrhythmias and sudden death (33) .
Evidence for idiopathic cardiomyopathy
Heart failure and reduced systolic function without evidence for any of the above etiologies or other disease known to cause cardiomyopathy.
Familial cardiomyopathy
• Possible familial cardiomyopathy: presence of otherwise unexplained cardiomegaly, diagnosis of heart failure, atrial fibrillation or life-threatening ventricular arrhythmias, conduction system disease, or sudden death in first degree relative under 60 years of age • Probable familial cardiomyopathy: presence of above in two relatives under 60 years of age who are related to each other and the patient
E. Laboratory Tests
When collecting information about laboratory tests, the minimum suggested data to capture are: 1) value, 2) unit of measurement, 3) date, and 4) normal range (upper limit of normal when appropriate 
F. Diagnostic Procedures (Table 5)
Diagnostic procedures may be noted as either having been performed or the findings described. Date of procedure should be recorded. Heart failure attributed to sustained (usually greater than 1 week) tachycardia (usually greater than 120 beats per min) that is not attributable to any other cause and shows evidence for improvement after correction.
Evidence for ventricular dysynchrony
Ventricular dysynchrony evidenced by QRS greater than or equal to 120 ms, intraventricular conduction delay (IVCD), bundle branch block (BBB).
Heart failure stage (17) • A ϭ patient at high risk for developing heart failure but who has no structural disorder of the heart • B ϭ patient with a structural disorder of the heart but who has never developed symptoms of heart failure • C ϭ patient with past or current symptoms of heart failure associated with structural heart disease • D ϭ patient with end-stage disease who requires specialized treatment strategies such as mechanical circulatory support, continuous inotropic infusions, cardiac transplantation or hospice care New York Heart Association (NYHA) class (30) NYHA class as reported by a physician: • Class I: patients with cardiac disease but without resulting limitations of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, or dyspnea. • Class II: patients with cardiac disease resulting in slight limitation of physical activity. They are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, or dyspnea. • Class III: patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary activity causes fatigue, palpitation, or dyspnea. • Class IV: patients with cardiac disease resulting in inability to carry on any physical activity without discomfort.
Symptoms are present even at rest or minimal exertion.
Health status (see Appendix A)
Health status of patient at the time of visit as documented by one of the following: Computerized axial tomography of the chest.
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• Ejection fraction: document ejection fraction percentage if measured as part of the CT scan • Ventricular volume assessment • Regional wall motion assessment Heart biopsy Biopsy of the endomyocardium.
Positron emission tomography (PET)
Positron emission tomography of the myocardium including perfusion imaging and stress studies. Documented findings may include:
• PET metabolic deficits • PET baseline perfusion deficits • PET metabolic/perfusion mismatch
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G. Invasive Therapeutic Procedures (Table 6)
Many cardiovascular diseases that either play a role in causing HF or influence its course are treated with invasive therapeutic procedures. A uniform description of the type of procedure and its indication for use would enhance coher-ence between clinical and research databases used to follow patients with HF. The procedures listed in this section are among those frequently applied to patients who may have either impaired cardiac function or clinical HF. Date and indication should be specified for all procedures. Table 6 . Invasive Therapeutic Procedures
Data Element Definition
Surgical Procedures
Coronary artery bypass graft (CABG) surgery
The number and types of grafts and surgical approach may be further specified:
• Number and placement of vein bypass grafts • Number and placement of arterial bypass grafts • Standard bypass surgery approach Approach may be further specified:
• Median sternotomy approach • Small thoracotomy • With or without cardiopulmonary bypass Transmyocardial laser revascularization (TMLR) Transmyocardial laser revascularization (TMLR) performed either alone or in combination with CABG.
Valve repair
Mitral, aortic, and/or tricuspid valve surgical repair. Use of valve ring may be specified. Valve(s) and procedure(s) may be specified. 
H. Pharmacological Therapy (Table 7)
For each pharmacological therapy element, administration or prescription of a medication in the specified class should be noted. In addition, particularly for clinical care, consider recording specific medication, total daily dose, start date, and stop date (when applicable). For combination therapies (e.g., combination diuretic and ACE inhibitor), both classes of medications should be indicated. Accurate and complete information about pharmacological therapy can be facili-tated by appending a list of drugs in each class that are commonly available for the setting and population under evaluation.
For all medications recommended with Class I evidence supporting the ACC/AHA Clinical Performance Measures for Heart Failure (19) , it is prudent to collect all potential contraindications. As of now, those medications include ACE inhibitors, beta-blockers, and warfarin anticoagulation (for patients with atrial fibrillation). 
Circulatory/Ventilatory Support
Extra-corporeal circulatory support
Extra-corporeal circulatory support includes:
• Intra-aortic balloon counterpulsation (IABP) • Extracorporeal membrane oxygenation (ECMO) Mechanical ventilatory support Mechanical ventilatory support includes:
• Mechanical ventilation/intubation • CPAP • BiPAP Specify dates of initiation and termination of therapy. Table 7 . Pharmacological Therapy
Data Element Definition
Therapies for HF
Aldosterone inhibitor
Patient has been prescribed an aldosterone inhibitor.
Angiotensin-converting enzyme (ACE) inhibitor medication
Patient has been prescribed an angiotensin-converting enzyme (ACE) inhibitor.
Angiotensin II receptor blocker (ARB) medication
Patient has been prescribed an angiotensin receptor antagonist blocker (ARB) medication.
Beta-adrenergic antagonist (beta-blocker) medication
Patient has been prescribed a beta-adrenergic antagonist (beta-blocker) medication.
Digitalis
Patient has been prescribed digitalis.
Diuretic medication
Patient has been prescribed a diuretic. Aldosterone inhibitor is listed separately above. 
Electrolytes
Oral vasodilators
Patient has been prescribed an oral vasodilator, other than specified in any above classes. Oral vasodilators most commonly prescribed for heart failure are nitrates (see "Nitrate therapy") and hydralazine. Other oral vasodilators may be prescribed to treat hypertension.
Oxygen therapy Patient has been prescribed oxygen for chronic use.
Antiarrhythmic agent Antiarrhythmic drug administered. As antiarrhythmics other than amiodarone are generally contraindicated in patients with heart failure, specific indications for their use should be noted.
Calcium channel blockers Calcium channel blockers administered. As calcium channel blockers are generally contraindicated in patients with heart failure, specific indications for their use should be noted.
Lipid-lowering agent
Lipid-lowering agent administered. Note the type of agent: statin (HMG Co-A reductase inhibitors), fibrates, nicotinic acid, resin drugs, other.
Aspirin
Patient has been prescribed aspirin.
Non-aspirin anti-platelet agent Patient has been prescribed a non-aspirin anti-platelet agent.
Warfarin
Patient has been prescribed warfarin. Target INR may also be helpful to collect.
Heparin
Patient has been prescribed heparin. Type of heparin may be specified.
Antidepressants
Patient has been prescribed an antidepressant.
Female hormone replacement therapy Patient has been prescribed female hormone replacement therapy.
Influenza immunization
Patient has been immunized for influenza.
Inhaled bronchodilator
Patient has been prescribed an inhaled bronchodilator.
Insulin
Patient has been prescribed insulin.
Non-steroidal anti-inflammatory drug (NSAID) Patient has been prescribed a non-steroidal anti-inflammatory drug. As NSAIDs are generally contraindicated in patients with heart failure, specific indications for their use should be noted.
Oral hypoglycemic agent Patient has been prescribed an oral hypoglycemic agent for treatment of diabetes. Specify agent.
Pneumococcal immunization
Patient has been immunized for pneumococcal pneumonia.
Vitamins, food supplements, and other nonprescription treatments
Therapy should be specified and may include vitamins, food supplements, homeopathic treatments.
I. End-of-Life Management (Table 8)
Patients' preferences for treatment, particularly life-sustaining treatments, change over time. Providers need to assess patients' preferences regularly to help patients and family members make the appropriate choices and decisions.
Patients with HF who are near the end of life experience dyspnea and pain, and providers need to work to assure that symptoms are adequately managed and that patients remain as comfortable as possible (35) . Patients and family members also require assistance from nurses and physicians in dealing with anxiety and loss.
J. Patient Education: Assessment of Status (Table 9)
Factors that negatively influence learning and self management, including cognitive impairment, low literacy or language skills, visual disturbances, depression, and lack of family or caregiver support, are common among HF patients (36 -38) , and should be assessed prior to educating patients. Additionally, patients' understanding of and adherence to care recommendations should be assessed regularly. 
Data Element Definition
Limitation of resuscitation Any documented order or decision regarding patient request to limit a component of emergency therapy to restore circulation or ventilation (e.g., no intubation, no chest compressions).
Do not resuscitate (DNR) Explicit documentation by physician and/or patient indicating that no resuscitative efforts are to be performed in the event of circulatory or respiratory arrest.
Inactivation of ICD defibrillation mode
Documentation of inactivation of ICD defibrillation mode without plans to re-activate (excludes inactivation for specific surgical procedures).
Advance care planning Documentation of discussion carried out with the patient and/or family (by physician or nurse) about advance directive. 
Data Element Definition
Assessment of Learning Readiness
Presence of cognitive impairment Documentation in the medical record that patient is cognitively impaired. Documentation may take the form of a qualitative statement (for example, dementia) or a score on a formal mental status assessment.
Low literacy skills Documentation in the medical record that the patient does not read or write well or is unable to read or write.
Language skills Documentation in the medical record of the patient's preferred language for communication.
Visual disturbances Documentation in the medical record that the patient has impaired sight (e.g., blindness, partial blindness, macular degeneration).
Hearing impairment (uncorrected) Documentation in the medical record that the patient has an uncorrected hearing impairment.
Depression
Documentation in the medical record that the patient carries the diagnosis of depression, or that the patient demonstrates depressed mood or affect. (See section on "Medical History: Non-Cardiovascular").
Level of caregiver/family support Documentation in the medical record of the living situation of the patient and level of support available to the patient in current living situation. Usually this is described as good, adequate, or inadequate, or a specific problem with family support is identified.
K. Patient Education: Intervention and Referral (Table 10)
Essential components of an educational program for patients with HF have been identified by several authors (22, 39, 40 Advice given or discussion carried out with the patient and/or family regarding diet counseling. May include:
• Sodium restriction • Fluid restriction • Other (specify) Counseling about alcohol abstinence/restriction Advice given or discussion carried out with the patient and/or family regarding the importance of abstaining from or reducing intake of alcohol (43, 44) .
Activity counseling
Advice given or discussion carried out with the patient and/or family regarding activity level and restrictions in activity, and/or exercise recommendations.
Smoking cessation counseling Advice given or discussion carried out with the patient (by physician, nurse, or other personnel) regarding the importance of stopping smoking. May include:
• Counseling (may be basic or advanced) • Written materials • Referral to smoking cessation program • Nicotine replacement therapy Immunization counseling Advice given or discussion carried out with the patient and/or family regarding the importance of obtaining influenza and pneumococcal immunizations. 
Data Element Definition
Assessment of Learning Readiness, continued
Medication adherence history History confirming adherence to medication regimen in the past.
Nutrition history
History confirming adherence to instructions regarding adequate nutrition.
Low-sodium diet history History confirming adherence to dietary sodium restriction in the past.
Smoking cessation history
If a current smoker, has the patient undergone smoking cessation counseling in the past?
Alcohol abstinence history History confirming adherence to alcohol abstinence, if patient has history of alcohol abuse.
Activity level history History confirming adherence to activity level and exercise program.
Daily weight history
History confirming adherence to self-monitoring of daily weight.
Daily blood pressure/heart rate history History confirming adherence to self-monitoring of daily blood pressure and heart rate.
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APPENDIX A: Health Status
Improving health status, decreasing patients' symptoms, and improving function and quality of life are primary goals for HF treatment and represent important outcomes for HF care. The Institute of Medicine, in Crossing the Quality Chasm (45) , calls for a fundamental restructuring of the entire American health care system to establish a greater focus on optimizing patient-centered outcomes such as health status. It follows that systematic assessment using validated instruments should be incorporated into prospective clinical trials, into quality assessment registries, and ultimately insinuated throughout the process of HF care. Although such systematic assessment is not currently part of routine clinical practice, an overview of health status assessment is included in this clinical data standards document so that future applications may be more easily served. For clinicians and others who are interested in systematically assessing the health status of their HF patients, several choices for measures exist (32, 46) . They fall into three general types: single-item summary measures; generic health status measures; and disease-specific instruments. Single-item summary measures are simple and quick to use, but they provide few details about the components of patients' health status, may not be reproducible, and could have limited sensitivity to important clinical change.
Generic measures allow comparison across disease states, and capture the health status limitations of co-morbid conditions. Because these measures may be influenced by factors other than patients' HF status, they may lack the reproducibility and sensitivity to changes in HF status desired for many of the applications anticipated in this document. Information gleaned using disease-specific measures is directly relevant to HF care, and is generally more clinically interpretable, more reliable, and more sensitive to clinical change than other assessment techniques. An overview of various instruments for each of these assessment techniques is provided in Table A1 .
There is some lack of clarity with regard to the domains of health status that are being quantified with specific instruments. In fact, authors frequently use the words "symptoms," "function," "functional status," "quality of life," and "health status" interchangeably. Figure A1 is designed to provide a framework of the different components of health status (used to represent the total of patients' experiences of symptoms, function, and quality of life). Modified from the concept of Wilson and Cleary (47) for patients with HF (48), it describes the underlying disease process of left ventricular dysfunction and neurohormonal imbalance that is manifested in patients as symptoms of fatigue, edema, and dyspnea. These symptoms can, in turn, affect patients' physical, emotional, cognitive, and social function. 
